Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Andrew S Talbot, Nigel T Lewis, Kathy M Nicholls
Heart | Published : 2015
OBJECTIVES: Assess the impact of end-stage renal disease (chronic kidney disease stage 5 (CKD5)) on cardiovascular outcomes in patients with Fabry disease on enzyme replacement therapy. BACKGROUND: Fabry disease, an X-linked lysosomal storage disease, causes hypertrophic cardiomyopathy and cardiovascular dysfunction. METHODS: Cardiac and renal function of 25 male patients with Fabry disease were analysed at 0, 1, 2, 5, 7 and 10 years after initiation of treatment. Patients were grouped at baseline into those with CKD5 (n=10) and those without (n=15). ECG and echocardiography were performed 6 and 12 monthly, respectively, while renal function was measured yearly. RESULTS: After 10 years of tr..View full abstract